BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25039889)

  • 1. Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
    Ozeki A; Amiya E; Watanabe M; Hosoya Y; Takata M; Watanabe A; Kawarasaki S; Nakao T; Watanabe S; Omori K; Yamada N; Tahara Y; Hirata Y; Nagai R
    J Clin Hypertens (Greenwich); 2014 Aug; 16(8):591-8. PubMed ID: 25039889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
    Giles TD; Alessi T; Purkayastha D; Zappe D
    J Clin Hypertens (Greenwich); 2012 May; 14(5):299-306. PubMed ID: 22533656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study.
    Spanos G; Kalaitzidis R; Karasavvidou D; Pappas K; Siamopoulos KC
    J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):315-21. PubMed ID: 23132848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG
    Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of the renin system by aliskiren and valsartan.
    Oparil S; Yarows SA; Patel S; Zhang J; Satlin A
    Lancet; 2007 Sep; 370(9593):1126-7. PubMed ID: 17905160
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
    Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
    Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.
    Geiger H; Barranco E; Gorostidi M; Taylor A; Zhang X; Xiang Z; Zhang J
    J Clin Hypertens (Greenwich); 2009 Jun; 11(6):324-32. PubMed ID: 19527323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
    Yarows SA
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.
    Suzuki H; Okada K; Abe M; Maruyama N; Yoshida Y; Baba S; Takashima H; Soma M
    Clin Exp Nephrol; 2013 Jun; 17(3):386-95. PubMed ID: 23135868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
    Serebruany VL; Pokov AN; Aradi D; Can M; DiNicolantonio J; Kipshidze N; Atar D
    Am J Ther; 2014; 21(6):482-90. PubMed ID: 23698186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.